Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies01:27

Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies

Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Acute exacerbation in fibrotic interstitial lung disease: An International Working Group Report.

American journal of respiratory and critical care medicine·2026
Same author

The LTI-01-2001 phase 2a trial of intrapleural LTI-01 in patients with infected, non-draining pleural effusions.

Respiratory research·2026
Same author

Toll-like receptor 5 protects against murine lung fibrosis through reduced dysbiosis, and <i>TLR5</i> deficiency is associated with human IPF.

Science translational medicine·2026
Same author

Genome-wide association study of idiopathic pulmonary fibrosis susceptibility using clinically curated European ancestry datasets.

The European respiratory journal·2026
Same author

Safety and Efficacy of Inhaled Natural Product Powders That Enhance Mucociliary Clearance.

AAPS PharmSciTech·2026
Same author

Persistence of alveolar fibroblast-derived ADAMTS4+ cells in a preclinical model of delayed pulmonary fibrosis resolution.

Nature communications·2026

相关实验视频

Updated: Jun 26, 2026

Adoptive Transfer of IL-33-Stimulated Macrophages into Bleomycin-Induced Mouse Models to Study Their Effect on Idiopathic Pulmonary Fibrosis In Vivo
06:29

Adoptive Transfer of IL-33-Stimulated Macrophages into Bleomycin-Induced Mouse Models to Study Their Effect on Idiopathic Pulmonary Fibrosis In Vivo

Published on: May 5, 2023

3.0K

吸入LTI-03治疗异形性肺纤维化:随机剂量升级研究

Philip L Molyneaux, Nikhil A Hirani, Collin C K Chia

    medRxiv : the preprint server for health sciences
    |November 24, 2025
    PubMed
    概括

    在一项1b期研究中,LTI-03是一种治疗异常性肺纤维化 (IPF) 的吸入疗法,证明了良好的安全性和耐受性. 生物标志物分析表明,IPF患者可能具有抗纤维和上皮保护作用.

    更多相关视频

    Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis
    06:03

    Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

    Published on: May 9, 2025

    1.6K
    Refined Murine Model of Idiopathic Pulmonary Fibrosis
    07:51

    Refined Murine Model of Idiopathic Pulmonary Fibrosis

    Published on: June 17, 2025

    878

    相关实验视频

    Last Updated: Jun 26, 2026

    Adoptive Transfer of IL-33-Stimulated Macrophages into Bleomycin-Induced Mouse Models to Study Their Effect on Idiopathic Pulmonary Fibrosis In Vivo
    06:29

    Adoptive Transfer of IL-33-Stimulated Macrophages into Bleomycin-Induced Mouse Models to Study Their Effect on Idiopathic Pulmonary Fibrosis In Vivo

    Published on: May 5, 2023

    3.0K
    Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis
    06:03

    Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

    Published on: May 9, 2025

    1.6K
    Refined Murine Model of Idiopathic Pulmonary Fibrosis
    07:51

    Refined Murine Model of Idiopathic Pulmonary Fibrosis

    Published on: June 17, 2025

    878

    科学领域:

    • 肺部医学 肺部医学
    • 药理学 药理学是指药理学的学科.
    • 纤维化研究 纤维化研究

    背景情况:

    • 异形性肺纤维化 (IPF) 缺乏有效的治疗方法来阻止疾病的进展.
    • 目前的IPF疗法往往会引起全身副作用,导致治疗中止.
    • LTI-03是一种新型的吸入治疗药物,向洞穴支架域 (CSD) 来补充丢失的Cav-1信号,在临床前模型中显示出前景.

    研究的目的:

    • 在IPF患者中评估吸入LTI-03的安全性和药理动力学 (PK).
    • 评估LTI-03对疾病生物标志物的影响.
    • 在IPF患者中探索LTI-03的剂量相关影响.

    主要方法:

    • 阶段1b,随机,受控,剂量升级研究.
    • 24名IPF参与者随机分为3:1到吸入LTI-03 (5或10毫克/天) 或安慰剂,持续14天.
    • 主要终点:与治疗相关的不良事件 (TEAE);次要:血中的PK和生物标志物变化,PBMC和DBB.

    主要成果:

    • 吸入LTI-03的耐受性很好,TEAE轻度至中度;没有停止.
    • 咳是最常见的TEAE.
    • 在深层支气管刷术中,LTI-03降低了IL-11,CXCL7,TSLP和Galectin-7的表达,对原蛋白和SP-D有剂量相关的影响.

    结论:

    • 吸入的LTI-03在14天内在IPF患者中显示出良好的安全性和耐受性.
    • 生物标志物数据表明,对上皮质平衡和抗纤维活性有积极影响.
    • 这些结果支持在IPF的第二阶段疗效研究中对LTI-03进行进一步的研究.